Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, today announced that it has extended and expanded its collaboration with New Jersey Urology, LLC (“NJU”). Pursuant to the extension, NJU will continue to provide patient samples for Anixa’s ongoing Cchek™ early cancer detection study. Further, the collaboration has been expanded to include support of clinical validation of Anixa’s Cchek™ Prostate Cancer Confirmation test with Anixa’s commercialization partner, ResearchDx.
Dr. Adam Perzin, who will continue to serve as the Principal Investigator at NJU for the study, stated, “We’re excited about expanding our collaboration and helping Anixa towards commercialization of this test, as the PSA test for prostate cancer is not ideal.”
“NJU continues to be a key collaborator in the development of Cchek™, our artificial intelligence driven liquid biopsy for early cancer detection, and we are pleased that this collaboration has been extended,” stated Dr. Amit Kumar, CEO of Anixa. “Further, we look forward to NJU’s participation as we begin the clinical validation phase of Cchek™ in preparation for the commercial launch of our Cchek™ Prostate Cancer Confirmation test in the third quarter of this year,” added Dr. Kumar.
